FDA 483 - Nordmark Arzneimittel GMBH & Co. KG - February 13, 2025
Discuss this record with AI
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.
Nordmark Arzneimittel GMBH & Co. KG, a drug substance manufacturer in Uetersen, Germany, was inspected by the FDA and received four observations. The inspection revealed significant issues with quality unit procedures, including failure to investigate root causes for contamination and deviations, lack of evidence for representative sampling, and non-contemporaneous documentation practices. These findings indicate a need for improved quality control and data integrity.
ID · 224c37dc-569f-4745-ba9a-33fc53d845e5